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Welcome to the third Edition of Clinical Ophthalmology of 2007. In this issue, we 
offer our usual wide range of original research papers covering clinical and basic 
sciences. 
We have a number of papers on surgical ophthalmology such as Agarwal and 
colleagues (2007), who describe the use of the very small incision Microphakonit 
in cataract surgery. Clinical papers include the pooled results of two randomized 
trials comparing ﬁ  xed versus loose combinations of travaprost and timolol (Gross 
et al 2007) and the use of eye movement measurements in multiple sclerosis. There 
are some excellent review articles including tips on the diagnosis and management 
of primary intraocular lymphoma (Jahnke et al 2007). Basic laboratory sciences are 
represented and readers will enjoy the results from Mizuki and colleagues, who look 
at the genetics of myopia (Sasaki et al 2007; Yamane et al 2007). 
It is particularly enjoyable to publish articles that contain an element of specula-
tion. For example, the possible use of oral acetazolamide as a treatment option for 
blepharochalasis (Lazaridou et al 2007) and a potential role for angiotensin-converting 
enzyme inhibitors in the treatment of glaucoma (Hirooka et al 2007). It is often a 
younger journal such as Clinical Ophthalmology that is more willing to publish these 
more speculative articles. In a world where new research is increasingly difﬁ  cult to 
do due to red tape, ﬁ  nancing, and sheer lack of time, publishing this type of research 
seems to be increasingly important. It is something we will continue trying to do as 
the years go by and the journal become more established.
More generally, the days when clinical specialties are dominated by a few long-
established journals are fading. It is an increasing demand of practitioners that they need 
access to high-quality up to date information. This has come not only from increased 
patient pressure for the ‘best’ treatment but the realisation that the means to rapidly 
disseminate cutting edge research now exists. What has now become the obstacle to 
accessing this research is ﬁ  nance. Most large publishers make their proﬁ  ts from library 
subscriptions or pay per view downloads by individuals. Increasingly funding bodies, 
including governments, have become unhappy with this situation as much research is 
publicly funded but is then published in journals that make a proﬁ  t by limiting access 
to both other researchers and the public. This situation has led to the Open Access 
(OA) movement that aims to make research freely accessible to anyone with internet 
access. The ﬁ  nancial model is that the author (or their institution or funder) pays a 
publication fee that allows free access to their entire paper in perpetuity. 
What are the advantages of this? To the reader it is obvious, and the advantages 
are also obvious for University libraries. Research funding bodies can clearly dem-
onstrate the end results of their often signiﬁ  cant investments. Perhaps the advantages 
to the authors are less obvious–after all, any money spent on publication is money 
potentially taken away from funding future research. This is a short-term view as 
having your latest paper immediately available is a good way to let the world know 
what you are doing. Arguably, OA research will be more frequently cited (as fellow 
researchers are able to access the complete paper) and thus OA-published research is 
more likely to have an impact (and perhaps meaning funding applications are more 
likely to succeed). Researchers from developing countries are not disadvantaged 
as they can apply to the publisher for a waiving of publication fees. In this way, 
Scott G Fraser
Sunderland Eye Infirmary; University 
of Sunderland; University Newcastle-
Upon-Tyne. Queen Alexandra Road, 
Sunderland, UK
EDITORIAL FOREWORDClinical Ophthalmology 2007:1(3) 200
Fraser
OA can actually encourage the publication of articles from 
developing countries, which have historically been under-
represented in the medical literature despite a greater burden 
of disease (Mandal et al 2005).
Dove Medical Press (publishers of Clinical Ophthal-
mology) is producing an increased number of OA journals 
in an attempt to make research ﬁ  ndings more widely avail-
able. Clinical Ophthalmology is fortunate to be one of the 
journals that will increasingly be OA. You can follow this 
process either by looking to the Clinical Ophthalmology site 
(see http://www.dovepress.com/articles.php?journal_id=64) 
or by going to the new Dove Open Access site where you 
will see the other OA journals available (see http://www.
doveoa.com/). 
There are ﬁ  erce advocates for both open and closed access 
publishing systems and it may be that medical publishing 
will end up with a mix of methods. I think most of us (as 
well as our patients) will hope the days when we unable to 
get hold of an important article because our library does not 
subscribe to it are nearing an end. 
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